The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in .sup.18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.

O-substituted hydroxamic acids with carbon-based leaving groups as HNO donors are disclosed. Pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions also are disclosed.

O-substituted hydroxamic acids with carbon-based leaving groups as HNO donors are disclosed. Pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions also are disclosed.

Small molecules and methods of treating cancer, a bacterial infection, and/or a fungal infection. The small molecules are chromenone derivatives. They have antimicrobial properties and are cytotoxic towards colon, liver, and breast cancer cell lines.

Small molecules and methods of treating cancer, a bacterial infection, and/or a fungal infection. The small molecules are chromenone derivatives. They have antimicrobial properties and are cytotoxic towards colon, liver, and breast cancer cell lines.

Disclosed is a configurational stereoisomer, referred to as enantiomer E.sub.4, of flocoumafen, the enantiomer E.sub.4 having, as determined by the chromatographic analysis of flocoumafen including four configurational stereoisomers of flocoumafen, carried out under conditions described hereinafter, a retention time t.sub.4 with a value such that t.sub.1<t.sub.2<t.sub.3<t.sub.4; t.sub.1, t.sub.2 and t.sub.3 representing the retention times of the configurational stereoisomers of flocoumafen different from the enantiomer E.sub.4, the analysis being carried out at a temperature of 23.5 C.

Disclosed is a configurational stereoisomer, referred to as enantiomer E.sub.4, of flocoumafen, the enantiomer E.sub.4 having, as determined by the chromatographic analysis of flocoumafen including four configurational stereoisomers of flocoumafen, carried out under conditions described hereinafter, a retention time t.sub.4 with a value such that t.sub.1<t.sub.2<t.sub.3<t.sub.4; t.sub.1, t.sub.2 and t.sub.3 representing the retention times of the configurational stereoisomers of flocoumafen different from the enantiomer E.sub.4, the analysis being carried out at a temperature of 23.5 C.

Disclosed is a configurational stereoisomer, named enantiomer E.sub.1, of flocoumafen, the enantiomer E.sub.1 having, by chromatographic analysis of flocoumafen performed under particular conditions, a retention time t.sub.1 having a value such that t.sub.1<t.sub.2<t.sub.3<t.sub.4; t.sub.2, t.sub.3 and t.sub.4 representing the retention times of the configurational stereoisomers of flocoumafen different from the enantiomer E.sub.1, the analysis being performed at a temperature of 23.5 C.

Disclosed is a configurational stereoisomer, named enantiomer E.sub.1, of flocoumafen, the enantiomer E.sub.1 having, by chromatographic analysis of flocoumafen performed under particular conditions, a retention time t.sub.1 having a value such that t.sub.1<t.sub.2<t.sub.3<t.sub.4; t.sub.2, t.sub.3 and t.sub.4 representing the retention times of the configurational stereoisomers of flocoumafen different from the enantiomer E.sub.1, the analysis being performed at a temperature of 23.5 C.

Disclosed is a composition including flocoumafen and an amount of a configurational stereoisomer of flocoumafen, named enantiomer E.sub.4, such that the ratio of this amount to the amount of flocoumafen in the composition is less than 10%, the enantiomer E.sub.4 being present with the exclusion of a racemic mixture, the enantiomer E.sub.4 having, by chromatographic analysis of flocoumafen, a retention time t.sub.4 having a value such that t.sub.1<t.sub.2<t.sub.3<t.sub.4; t.sub.1, t.sub.2 and t.sub.3 representing the retention times of the configurational stereoisomers of flocoumafen different from the enantiomer E.sub.4, the chromatographic analysis being performed at a temperature of 23.5 C.